Literature DB >> 2457279

Characterization of homotypic and heterotypic VP7 neutralization sites of rhesus rotavirus.

E R Mackow1, R D Shaw, S M Matsui, P T Vo, D A Benfield, H B Greenberg.   

Abstract

The gene 9 nucleotide sequence was determined for rhesus rotavirus and each of 14 viral variants selected for their resistance to neutralizing monoclonal antibodies. Each variant contains a single gene 9, VP7, mutation which permits viral growth in the presence of the antibody. Variant mutations were identified in two distinct neutralization regions. Region A was identified by monoclonal antibodies that are involved in both serotype-specific and serotype cross-reactive neutralization. Region C was identified by serotype-specific neutralizing monoclonal antibodies. Heterotypic neutralizing monoclonal antibody 57-8 selected variants with a mutation at amino acid 94 in the A region, the same amino acid location selected by serotype-specific monoclonal antibodies. Monoclonal antibody 3 selected a VP7 mutation at amino acid 99 resulting in additional N-linked glycosylation of the VP7 protein. Despite the added VP7 glycosylation, variant v3 was not broadly resistant to additional VP7-specific neutralizing monoclonal antibodies.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2457279     DOI: 10.1016/0042-6822(88)90595-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  50 in total

1.  Evidence for two serotype G3 subtypes among equine rotaviruses.

Authors:  G F Browning; R M Chalmers; T A Fitzgerald; D R Snodgrass
Journal:  J Clin Microbiol       Date:  1992-02       Impact factor: 5.948

2.  Comparisons of rotavirus VP7-typing monoclonal antibodies by competition binding assay.

Authors:  P Raj; D O Matson; B S Coulson; R F Bishop; K Taniguchi; S Urasawa; H B Greenberg; M K Estes
Journal:  J Clin Microbiol       Date:  1992-03       Impact factor: 5.948

3.  A novel group A rotavirus G serotype: serological and genomic characterization of equine isolate FI23.

Authors:  G F Browning; T A Fitzgerald; R M Chalmers; D R Snodgrass
Journal:  J Clin Microbiol       Date:  1991-09       Impact factor: 5.948

4.  Diversity in Indian equine rotaviruses: identification of genotype G10,P6[1] and G1 strains and a new VP7 genotype (G16) strain in specimens from diarrheic foals in India.

Authors:  B R Gulati; R Deepa; B K Singh; C Durga Rao
Journal:  J Clin Microbiol       Date:  2006-11-29       Impact factor: 5.948

5.  Homotypic and heterotypic serological responses to rotavirus neutralization epitopes in immunologically naive and experienced animals.

Authors:  D R Snodgrass; T A Fitzgerald; I Campbell; G F Browning; F M Scott; Y Hoshino; R C Davies
Journal:  J Clin Microbiol       Date:  1991-11       Impact factor: 5.948

6.  Reactivities of serotyping monoclonal antibodies with culture-adapted human rotaviruses.

Authors:  R L Ward; M M McNeal; J D Clemens; D A Sack; M Rao; N Huda; K Y Green; A Z Kapikian; B S Coulson; R F Bishop
Journal:  J Clin Microbiol       Date:  1991-03       Impact factor: 5.948

7.  Operational overlapping of cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus serotype 3.

Authors:  N Kobayashi; K Taniguchi; S Urasawa
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

8.  Serological characterization of bovine rotaviruses isolated from dairy and beef herds in Argentina.

Authors:  R C Bellinzoni; J O Blackhall; N M Mattion; M K Estes; D R Snodgrass; J L LaTorre; E A Scodeller
Journal:  J Clin Microbiol       Date:  1989-11       Impact factor: 5.948

9.  The amino-terminal half of rotavirus SA114fM VP4 protein contains a hemagglutination domain and primes for neutralizing antibodies to the virus.

Authors:  M Lizano; S López; C F Arias
Journal:  J Virol       Date:  1991-03       Impact factor: 5.103

10.  Cross-reactive, serotype- and monotype-specific neutralization epitopes on VP7 of serotype G3 and G5 porcine rotavirus strains.

Authors:  M Ciarlet; M Hidalgo; F Liprandi
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.